================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
-------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 18, 2003
Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-30929 13-4087132
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
750 Lexington Avenue
New York, New York 10022
(Address of principal executive offices)
(212)-531-5965
(Registrant's telephone number, including area code)
================================================================================
Item 5. Other Events
On November 18, 2003 Keryx Biopharmaceuticals, Inc. announced the
private placement of approximately 3.5 million shares of its common stock and
warrants to purchase an additional 705,000 shares of common stock. The November
18, 2003 Press Release relating to the private placement is incorporated herein
by reference and is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
The following exhibit is filed as a part of this report:
Exhibit
Number Description
------ -----------
99.1 Press Release dated November 18, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Keryx Biopharmaceuticals, Inc.
(Registrant)
Date: November 18, 2003 By: /s/ Michael S. Weiss
------------------------------------
Michael S. Weiss
Chairman and Chief Executive Officer